Somatic PALB2 loss-of-function in breast: small TBCRC-048 cohort included sPALB2 with PAR...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-PALB2-SOMATIC-BREAST |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-BREAST |
| Sources | SRC-CIVIC SRC-ESMO-BREAST-METASTATIC-2024 SRC-NCCN-BREAST-2025 |
Actionability Facts
| Biomarker | BIO-HRR-PANEL |
|---|---|
| Variant | PALB2 somatic loss-of-function |
| Disease | DIS-BREAST |
| ESCAT tier | IIB |
| Recommended combinations | olaparib (off-label), talazoparib (off-label) |
| Evidence summary | Somatic PALB2 loss-of-function in breast: small TBCRC-048 cohort included sPALB2 with PARPi response; off-label PARPi consideration per NCCN. ESCAT IIB / OncoKB Level 3B. |
Notes
Reflex germline testing recommended.
Used By
No reverse references found in the YAML corpus.